PolyPeptide Group AG

The Global Antimicrobial Peptides Market is projected to grow from US$223.90 Mn in 2023 to US$532.02 Mn by 2031, driven by biotechnology advances and health awareness. Key players include Novozymes A/S, Pfizer Inc., and GlaxoSmithKline plc. Challenges include stringent regulations and microbial resistance.

Hamlet BioPharma reports significant clinical progress in Q1 2024, including strong tumor responses in bladder cancer patients treated with Alpha1H and comparable efficacy of anakinra to antibiotics in recurrent cystitis. The company continues to advance its pipeline and strategic alliances, positioning itself for sustainable growth in high-demand markets for cancer therapies and infection control.

Peptide Therapeutics Market to grow from USD 43.11 billion in 2023 to USD 68.4 billion by 2031, driven by increasing prevalence of cancer and metabolic disorders, and advancements in drug delivery systems.

The oligonucleotide CDMO market is projected to grow from USD 2.51 billion in 2024 to USD 6.73 billion by 2029, with a CAGR of 21.8%. Key players include Thermo Fisher Scientific, Lonza, and Agilent Technologies. The market's expansion is driven by increasing demand for therapeutic, research, and diagnostic applications across pharma and biotech sectors.